IMI

Europe’s public-private Innovative Medicines Initiative (IMI) announced last week the launch of UNITE4TB—a $218 million, seven-year project to accelerate and improve the clinical evaluation of combinations of existing and novel drugs as treatment regimens for drug-resistant and drug-sensitive tuberculosis. UNITE4TB is the newest project of IMI’s AMR Accelerator.

The consortium—which involves 30 partners including academic institutions, GSK, J&J’s Janssen subsidiary, KNCV…

Mentions:

Two nonprofits accused European Commission public-private partnership Innovative Medicines Initiative (IMI) this week of yielding to industry demands that blocked research into rapid vaccine development.

In a 72-page report, Global Health Advocates and the Corporate Europe Observatory said that IMI—which currently claims a $3.6 billion budget funded equally by government and pharma—“invests in industry priorities over unmet social needs,” channeling public money into initiatives that…

The global effort to develop vaccines, drugs and diagnostics for Covid-19 saw new developments over the past week, including international partnerships and the launch of significant grants.

On vaccines, Inovio’s CEO used Monday’s pharma summit at the White House to announce accelerated clinical trials—beginning next month—of an investigational DNA-based vaccine, partly funded by the Coalition for Epidemic Preparedness Innovations (CEPI). In another CEPI-backed Covid-19 project,…

German biotech Evotec SE and Dutch nonprofit Lygature announced last week that they are launching Gram-Negative Antibacterials NOW (GNA NOW)—an initiative to develop novel antibacterial agents. GNA NOW includes nine other partner members from academia and industry and will progress three R&D programs in parallel, aiming to bring two into clinical development by 2024.

European public-private partnership the Innovative Medicines Initiative will match Evotec’s in-kind contribution…

Mentions:

Johnson & Johnson announced this week that its Janssen subsidiary and Europe’s Innovative Medicines Initiative have co-launched a research consortium with European universities and biotechs to discover and develop new TB treatments through two initiatives.

RESPIRI-TB will focus on developing new compounds from different drug classes that could be used with each other or with Janssen’s bedaquiline, while RESPIRI-NTM will work to build a pipeline of drug candidates for the non-TB…

Mentions: